Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform
Authors:
- Rajesh Thangavel YadavRYRajesh Thangavel Yadav
- Mansi SharmaMSMansi Sharma
- Santhosh Kambaiah NagarajSNSanthosh Kambaiah Nagaraj
- Rohan NarayanRNRohan Narayan
- Abinaya KaliappanAKAbinaya Kaliappan
- Uma ShanmugasundaramUSUma Shanmugasundaram
- Rahul ChavanRCRahul Chavan
- Akhila B. RaiARAkhila B. Rai
- Rashmi RaiRRRashmi Rai
- Thottethodi Subrahmanya Keshav PrasadTPThottethodi Subrahmanya Keshav Prasad
- Suryaprakash SambharaSSSuryaprakash Sambhara
- Rachit AgarwalRARachit Agarwal
Preprint
Abstract
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. GraphicalKeywords
All Related Versions
Funding Information
- DBT-ENDFLU (BT/IN/EU-INF/15/RV/19-20)
This publication has 68 references indexed in Scilit:
- Quantification of intracellular influenza A virus protein dynamics in different host cells after seed virus adaptationApplied Microbiology and Biotechnology, 2025
- Cationic inhalable particles for enhanced drug delivery to M. tuberculosis infected macrophagesMaterials Science and Engineering: C, 2022
- Modulation of Immune Responses by Particulate MaterialsAdvanced Materials, 2016
- Cytotoxic T cell vaccination with PLGA microspheres interferes with influenza A virus replication in the lung and suppresses the infectious diseaseJournal of Controlled Release, 2015
- Influenza Vaccines: Challenges and SolutionsCell Host & Microbe, 2015
- An overview of bioinformatics tools for epitope prediction: Implications on vaccine developmentJournal of Biomedical Informatics, 2015
- T cell mediated immunity to influenza: mechanisms of viral controlTrends in Immunology, 2014
- Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza VaccineJournal of Clinical Immunology, 2012
- Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypesImmunogenetics, 2011
- CD4+T Cells Are Ineffective in Clearing a Pulmonary Infection with Influenza Type A Virus in the Absence of B CellsVirology, 1997